drugset / Trial / NCT01295944
Carboplatin and Bevacizumab for Recurrent Ependymoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.
Timeline
- Start
- 2011-04-27
- Primary completion
- 2020-09-23
- Completion
- 2021-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Carboplatin | Small molecule | — | — |